HK Stock MarketDetailed Quotes

01548 GENSCRIPT BIO

Watchlist
  • 14.500
  • +0.300+2.11%
Market Closed Mar 28 16:08 CST
30.80BMarket Cap-41310P/E (TTM)

About GENSCRIPT BIO Company

Kingsri Biotechnology Co., Ltd. (the “Company” or “Kingsley”, together with its subsidiaries, collectively the “Group”) is a widely recognized biotechnology company. Based on our proprietary gene synthesis technology and other technology and expertise related to life science research and applications, we have successfully established four main platforms, including (i) a life science service and product platform to provide one-stop solutions for the global research community; (ii) a biologics contract development and production organization (“CDMO”) platform; (iii) an industrial synthesis product platform; and (iv) a comprehensive global cell therapy platform. For the six months ended June 30, 2023 (the “Reporting Period”), the above four internally built platforms achieved growth in R&D up to commercial delivery. Since its establishment 21 years ago, the Group has been adhering to the mission of “using biotechnology to make people and nature healthier”. The business needs of our customers are the Group's top priority and the fundamental foundation for our long-term development. We have been improving the competitiveness of our customers by providing quality, fast delivery and cost effective services and products. Internally, we focus on optimizing operating processes and procedures, aiming for the highest quality of end-to-end delivery. Externally, we actively enhance the value of strategic collaboration with business partners aimed at building a healthy biotechnology ecosystem. We hope to make greater contributions to accelerating the development of the entire biotech and biopharmaceutical industry to achieve a win-win situation among all partners involved in the industry. The Group's business operations cover more than 100 countries around the world, and its legal entities include mainland China (“China”), the United States, Hong Kong, Japan, Singapore, the Netherlands, Ireland, the United Kingdom, South Korea and Belgium. As of June 30, 2023, our professional team consists of around 6,414 members. The services and products provided by the Life Sciences Services and Products Division cover gene synthesis, oligonucleotide synthesis, peptide synthesis, protein production, antibody development, and life science equipment and consumables. By serving early research and discovery projects in pharmaceutical, biotechnology, and academic institutions, our business makes a significant contribution to the global life science research community. The CDMO platform provides one-stop cell and gene therapy (“CGT”) development and biologics discovery, development and subsequent production services for customers around the world. During the reporting period, the CDMO business focused on global production capacity and commercial network expansion. Legend Biotech Co., Ltd. (“Legend” or “Legend Bio”) is a biopharmaceutical subsidiary of the Group that specializes in the discovery and development of novel cell therapies for tumors and other indications. The legendary lead candidate, cilta-cel (cilta-cel), is a chimeric antigen receptor T-cell therapy developed in collaboration with JanssenBiotech, Inc. (“Janssen”) to treat multiple myeloma (“MM”). Baisjie Biotechnology Co., Ltd. (“Baisjie”) is a subsidiary of the Group and is engaged in the synthetic biology business. BESGER uses our advanced enzyme engineering technology to develop products for the feed, alcohol, food and home care industries. We believe synthetic biology provides us with new technological and commercial opportunities.

Company Profile

Symbol01548
Company NameGENSCRIPT BIO
ISINKYG3825B1059
Listing Date12/30/2015
Issue Price1.31
Shares Offered400.00M share
Founded05/21/2015
RegistrationCayman Islands
ChairmanJiange Meng
SecretaryHuiling Huang
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered Office4th Floor, Harbour Place 103 South Church Street, George Town P.O. Box 10240, Grand Cayman KY1-1002 Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees6937
MarketHong Kong motherboard
Phone(86)25588972886312
Fax(86)025588972885815
Emailorder@genscript.com.cn
Business Kingsley Biotechnology Co., Ltd. is a Hong Kong investment holding company mainly engaged in bioscience research and related businesses. The company operates through four major divisions. The Life Science Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid and nucleic acid primer synthesis, deoxyribonucleic acid sequencing, customized antibody services, protein expression and stable cell line production. The preclinical drug development services segment includes protein and antibody engineering, in vitro pharmacodynamics research, and in vivo pharmacodynamics research. The Life Science Research Catalogue product segment provides antibodies, recombinant proteins, protein separation and analysis instruments, molecular biology reagents, peptides, biochemical products and stable cell lines. The Industrial Synthetic Biological Products Division develops and produces industrial enzymes.

Company Executives

  • Name
  • Position
  • Salary
  • Fangliang Zhang
  • Strategy Committee Chairman,Chairman of the Risk Management Committee,Executive Director
  • --
  • Jiange Meng
  • Nomination Committee Chairman,VP,Chairman of the Board,Company Secretary,Executive Director,Authorized Representative
  • --
  • Ye Wang
  • President,Remuneration Committee Member,Executive Director,Chief Operating Officer
  • --
  • Li Zhu
  • Authorized Representative,Chief Strategy Officer,Executive Director
  • --
  • Luquan Wang
  • Non-Executive Director
  • --
  • Yuexin Pan
  • Strategy Committee Member,Non-Executive Director
  • --
  • Jiafen Wang
  • Non-Executive Director,Strategy Committee Member
  • --
  • Hongxin Guo
  • Audit Committee Member,Independent Non-Executive Director,Risk Management Committee Member,Remuneration Committee Chairman
  • --
  • Zumian Dai
  • Nomination Committee Member,Independent Non-Executive Director,Audit Committee Chairman,Remuneration Committee Member
  • --
  • Jiuan Pan
  • Audit Committee Member,Risk Management Committee Member,Independent Non-Executive Director,Nomination Committee Member
  • --
  • Xuehai Wang
  • Independent Non-Executive Director
  • --
  • Weihui Shao
  • CEO,Chief Operating Officer,CEO
  • --
  • Shiniu Wei
  • CFO
  • --
  • Ying Huang
  • Legendary Director,Legendary CEO and Chief Financial Officer
  • --
  • Huiling Huang
  • Company Secretary
  • --
  • Chifa Zhang
  • Head of the Industrial Synthetic Biological Products Division
  • --
  • Chuanchu Zhou
  • Head of the Preclinical Drug Development Services Business Division
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg